BioInItaly Newsletter

La vetrina del biotech italiano all’estero
  • 08 mar, 2016
    Sommario
    World’s first material formulations laboratory to make MINERV PHAs advanced bioplastic 
    Drug Discovery Collaboration between Grünenthal and Axxam
    Zambon Launches Xadago® (Safinamide) In Italy For Patients With  Mid- To Late-Stage Parkinson’s Disease 
    Axxam and the NEOMED Institute to Collaborate on the Discovery and Development of a Novel Drug to Treat Metabolic Diseases 
  • 09 feb, 2016
    Sommario
    Kedrion Biopharma strengthens its position on the US Market
    AbbVie invests in Italy: 60 million dollars in arrival to the manufacturing site
    Zambon launches Xadago® (Safinamide) in Switzerland for patients with parkinson’s disease
    BioInItaly Investment Forum 2016, where biotech meets investors. 19-20 April in Milan
  • 08 gen, 2016
    Sommario

    The European Commission grants Orphan Drug Designation to Sirolimus (Rapamycin) for the treatment of beta thalassaemia intermedia and major
    Science Translational Medicine published results of a study highlighting the role of memory stem T cells in the treatment of leukaemia
    Axxam and the Neurodegeneration Consortium at The University of Texas MD Anderson Cancer Center collaborate on a novel approach to Alzheimer’s disease research
    EryDel Consortium Gains € 6 million of EU Funding for Development of EDS  for the treatment of Ataxia Telangiectasia
    Capital Increase of  Flowmetric Europe
    Bioplastic created for the toys of the future safe and eco-sustainable, child-friendly and environmentally sound

  • 03 dic, 2015
    Sommario
    MolMed: AIFA granted authorization to manufacture gene therapies for marketing purposes
    Newron Completes 5.4 Million USD/CHF Private Placement with U.S. Biotechnology/Healthcare Specialist Fund
    Advanced Accelerator Applications S.A. listed on the US Nasdaq stock Exchange
    Newron initiates U.S. Phase II trial in patients with schizophrenia 
  • 02 nov, 2015
    Sommario
    Axxam executes agreement with NYU Langone Medical Center for the provision of drug discovery services
    Agena Bioscience and Diatech Pharmacogenetics Announce Plan to Launch Actionable, Targeted CE-IVD Marked Oncology Assays for Colon, Lung, and Melanoma Treatment
    Meiji announces initiation of Phase II/III and long-term clinical trials of safinamide inhibitor developd by Newron Pharmaceuticals S.p.A. for the treatment of Parkinson’s disease
    BioInItaly Investment Forum 2016, where biotech meets investors. 19-20 April in Milan
  • 02 ott, 2015
    Sommario
    International award for Bioindustry Park/bioPmed Cluster
    Agreement to realise the first France-based facility for producing PHAs biopolymers from sugar beet co-products
    Xadago® (safinamide) New Drug Application - Late-Cycle Review Meeting Completed with U.S. FDA
    Newron Receives FDA Orphan Drug Designation for Sarizotan for the Treatment of Rett Syndrome
    Boston-based Angus signed a €40M deal with the Italian Biotech Diatheva to Immuno-oncology Target CEACAM1
  • 03 ago, 2015
    Sommario
    Long term benefit of erythrocyte-delivered dexamethasone in Ataxia Telangiectasia
    TLS Bio-incubator “doubling”. New spaces and labs available for public and private open access research
    Axxam enters into a research collaboration with The University of Texas MD Anderson Cancer Center for Assay Development and High Throughput Screening of selected targets in oncology
    Newron Receives FDA Orphan Drug Designation for Sarizotan for the Treatment of Rett Syndrome
    Axxam SpA enters into a collaboration agreement with Bayer HealthCare for the provision of Drug Discovery Services
  • 03 lug, 2015
    Sommario
    TES Pharma and école Polytechnique Fédérale de Lausanne (EPFL) Announce R&D Collaboration on Small Molecule Therapies for Metabolic Disorders and Age-Related Diseases

    MolMed winner of sixth edition of the Annual Most Innovative EU Biotech SME Award
  • 30 apr, 2015
    Sommario
    Amgen receives EU approval for a new indication of Vectibix (panitumumab)
    MolMed expands its pipeline by entering the CAR-T field having exercised the option right on San Raffaele Hospital CAR-CD44v6 project
    Aptuit LLC and Axxam SpA announce Strategic Alliance for Integrated Drug Discovery Services
    CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO
    Advancing competent professionals in  Medicines Development, a PHARMATRAIN – IFAPP – SSFA CONFERENCE
  • 30 mar, 2015
    Sommario
    The Italian Biotech Start-up founded by San Raffaele Hospital, Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner, raised a Euro 10 million ($11 million) Series A round with the support of Banca Esperia
    Developing selective epigenetic drugs for leukemia: the European Institute of Oncology enters into a drug discovery collaboration with the biotech Rasna Therapeutics
    Takis to present encouraging data on stromal cancer vaccine at the American Association for Cancer Research
    THERAMetrics Holding AG and Centurion Pharma are currently finalizing an agreement relevant to the development, registration and distribution of Aviptadil in Sarcoidosis in Turkey and the MENA Region
    MolMed enters into a strategic collaboration with GSK for development, manufacturing and technology transfer in gene therapy
    Nicox receives Orphan Drug Designation from FDA for naproxcinod in Duchenne Muscular Dystrophy
  • 06 mar, 2015
    Sommario
    Lofarma biotechnology to fight moulds-allergy with drops
    THERAMetrics: through Innovation and Technology
    Celgene: a positive decision for NHS reimbursement of ABRAXANE®
  • 30 gen, 2015
    Sommario
    The Merck Serono S.p.A. plant in Modugno-Bari opened  its doors to the Department of Pharmacy  and Pharmaceutical Sciences of the Bari University
    A biomarker for nonalcoholic steatohepatitis (NASH)  
    Newron initiates Phase II study of sNN0029 in patients with Amyotrophic Lateral Sclerosis and of sNN0031 in patients with Parkinson’s disease